Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 30;16:5193–5209. doi: 10.2147/IJN.S321612

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Cai et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

In vivo magnetic resonance imaging (MRI) and synergetic anticancer therapy. (A) T2-weighted MR images of 786-O tumor-bearing mice (n = 3) at 0, 1, 3, 6, and 24 h post-injection of 15 mg Fe/kg body weight PF@PCM (top row) or tPF@PCM (bottom row). The white dotted circles represent tumors. (B) Schematic of the treatment regimen for 786-O tumor-bearing mice. (C) Tumor volume changes (n = 4) after different treatments. **P < 0.01. (D) Photos of the tumors extracted from mice in different groups at the end of treatments (day 15).